DRUGS · SERVICE DETAILS

OTC Monograph Path Support

The applicability of OTC monographs is judged from active ingredients, concentrations, formulations, uses and labels, and the registration of facilities, NDC, Drug Listing and follow-up maintenance. The need for NDA, ANDA or OMOR is assessed separately.

OTC means a non-prescription sales attribute and does not mean that all OTC products are subject to monographs. Products that meet the applicable statutory requirements are listed according to the corresponding rules; Registration, NDC or listing per se does not represent FDA approval.

SERVICE OVERVIEW

What does this service help with?

The question is whether the product can follow the OTC Monochorph path, and the information preparation and commissioning range. We list additional information and matters to be confirmed, taking into account specific formulations, uses, mode of delivery and applicable conditions for collating in English. In the case of new active ingredients, prescriptions or other non-satisfactions, further assessment should be made of such routes as listing applications or OOMOR, which cannot be sold only after registration.

WHO MAY NEED IT

Who should consider this service?

Non-prescriptive drugs are proposed for sale to manufacturers, brands or labels of formulations in the United States, as well as to enterprises that need to review existing OTC product compliance routes. Skin protection, sun protection or other products should be combined with components, uses and claims to be pharmaceuticals or cosmetics.

SCOPE & APPROACH

What are the matters that are usually checked by the OTC Monograph Project?

The following is the direction for collaboration between the assessment and the information; Specific deliverables, declarations and segregation of duties are subject to confirmed delegation.

01

Applicability of product classifications and monographs

Check the active ingredient and its concentration, formulation type, route of delivery, adaptiveness, usage and applicable population, against existing monographs, executive orders and related conditions.

02

Drug Facts and full labels

Combination of active ingredients, uses, warnings, usage, other information and non-active ingredients, and overall consistency of labels. The labelling review must be accompanied by applicable monographs, testing and product information.

03

Facilities registration, U.S. agent and product listing

Identify facilities, manufacturers and labelers ' roles, confirm the registration of pharmaceutical facilities, the division of application and information between U.S. agents, NDC Labeler Code and Drug Listing.

04

Quality information and detection gaps

To collate formulations, specifications, detection methods, stability and manufacturing quality information, identifying applicable monographs and cGMP-related pending confirmation; Actual testing or quality system work needs to be agreed upon separately.

05

OMUFA cost and maintenance arrangements

To determine whether or not to involve OTC specialized in drug facility fees and MDF/CMO classifications, and to comb information updating and maintenance matters. OOMOR application fees are to be judged separately from general facility registration, listing and service charges.

06

NDA, ANDA and OMOR Path Boundaries

Further assessment of the need for an NDA, ANDA or an application for an executive order (OMOR) if the qualifications of the monograph are not met. NDA/ANDA products require appropriate approval; This page service does not contain a complete application, clinical study or OMOR submission.

GET READY

It is recommended that these OTC products be prepared before the evaluation begins.

Existing information may be submitted first and gaps identified; Specific paths and workloads are based on product facts and follow-up checks.

  • Complete formulations: active and non-active ingredients, concentrations, formulations and modes of delivery
  • Intended use, adaptive condition, applicable population, usage and market declaration
  • Draft or current sales labels in English, including Drug Facts and overpacking
  • OTC monographs or executive orders to be applied, and authorization or transaction records already in place, if any
  • Information on manufacturing, packaging, labeling parties and offshore facilities, and FEI, NDC or listing records, if any
  • Information on specifications, detection, stability and manufacturing quality is available
HOW TO START

From product path to information and maintenance arrangements

STEP 01

Determining product and applicable path

Check compositions, uses and declarations, distinguishing between specialized products and the need for further assessment of listing applications.

STEP 02

Creating a list of information gaps

Gaps in labelling, testing, quality information, facilities and product information against applicable conditions.

STEP 03

Confirmation of delegation and cost scope

Clear review, documentation, registration listing or other work to be delivered and an indication of official fees, service fees and third party fees.

STEP 04

Engagement and maintenance

(c) To identify follow-up information on enterprises and the application of maintenance matters based on delegated collaboration, retention of submissions and feedback records.

The OTC Monograph Path should not be referred to as a uniform FDA authentication. The saleability of products should be judged by the combined application of monographs or approval routes, labels, quality and other statutory requirements; NDC and Drug Listing do not replace listing approvals.

TIMING & FEES

Timing and fees

Information reviewed:Fee period: FY 2027, October 1, 2026 through September 30, 2027. For other charges, use the FDA rules as of the review date.

Timing and preparation

Document preparation

The product scope, availability of information and verification depth determine the lead time; The opinio juris is completed before a plan of work is agreed for label review, documentation and registration of listings.

FDA processing

Monograph condition assessments are not equivalent to product approvals from FDA and do not give a single “approved” number of days to all OTC projects. Where NDA, ANDA or OMOR are required, the corresponding procedures, information and processing arrangements shall be assessed separately.

Fee breakdown

FDA fees

FY 2027 OMUFA: US$ 47,891, CMO US$ 31,927, applicable MDF facilities; OMER Tier 1 is US$614,608, Tier 2 is US$122,921. Whether or not to trigger and pay is judged by activity and application, general registration listings are not a substitute for these costs.

Service fees

Consulting and filing are quoted separately from FDA fees, based on the number of products, completeness of the records, work scope, response rounds and service term.

Other possible costs

Testing, translation, software and other third-party work are quoted separately where needed.

OFFICIAL SOURCES

Official basis for OTC paths, labels and fees

Official data check: 2026-11-06. The application of monographs, executive orders and costs shall be subject to the official version of the project at the time of its implementation.

START WITH YOUR PRODUCT

Tell us about your product so we can discuss the appropriate pathway.

Share intended use, ingredients or technical characteristics, production location, business role and current stage. We can use this information to discuss likely FDA requirements and service scope.